The thymus is an organ located under the breastbone. It is part of the lymphatic system and is responsible for producing white blood cells called lymphocytes that help fight infections. Thymus cancer is a disease in which there are cancer cells lining the outside of the thymus tissues.
The exact causes for the development of thymus cancer have not yet been elucidated. However, it has been proven that there are several pathologies of the immune system or hormonal disorders that manifest themselves when a person presents this disease. Myasthenia gravis is a more common autoimmune disease that manifests in 40% of cases linked to thymus cancer. In some cases it manifests in lupus erythematosus, thyroiditis, polymyositis, rheumatoid arthritis, hyperthyroidism, among others.
Escozul™ can be administered in conjunction with any conventional treatment. Escozul™ seeks to work not only on the cancer but also on the patient's quality of life. Its analgesic and anti-inflammatory effects help to improve the quality of life in about 65 to 75% of the patients treated. Through its antitumor effect, depending on the stage, one of the following results is expected: to be able to slow down the progression of the disease, to stop tumor growth, to reduce the size of lesions or to eliminate tumor lesions.
It is important to point out that Escozul™ is not considered a cure for cancer, it is a natural medicine that converts this deadly disease into a controlled chronic one, also offering quality of life.
Results in different cases
Thymus cancer with bone and lymph node metastases. Patient: Y.B.P. Age: 53
Patient diagnosed with thymus carcinoma with bone and lymph node metastases manages to overcome the disease after 9 months of treatment.Read more
Y.B.P. is a 53-year-old patient, who came to us in June 2017 with a diagnosis of thymus carcinoma with metastasis. At 9 months of Escozul™ treatment in conjunction with conventional treatments the patient has been discharged from oncology as there is no presence of disease.
Y.B.P. is a 53-year-old patient, who came to us in June 2017 with a diagnosis of thymus carcinoma with multiple metastases.
When we received the medical documentation we were able to ascertain that it was a thymus carcinoma with bone metastases and secondary lower cervical/left supraclavicular, antero-superior mediastinal and prevascular adenopathies. She was pending to start treatment with chemotherapy and radiotherapy.
Once the case had been analyzed by our specialists, we informed the patient's daughter about what to expect with Escozul™ and the possibilities of achieving good results.
Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.
Y.B.P. started treatment with Escozul™ in July 2017.
Evolution, Follow-up and Current Results:
Communication with Mr. Y.B.P.'s sister has been smooth during the time of treatment, which is very important as a function of monitoring the results and making necessary adjustments.
In the first control CT scan in August 2017, one month after treatment, an increase in the size of the mediastinal mass was observed with respect to the previous study, and in addition two secondary nodules were found in lungs. We proceeded at this time to an increase in dose, seeking to obtain better results in the next control.
By November 2017, new studies indicate a decrease in the size of the supraclavicular adenopathies.
In January 2018, the new chest CT scan showed a decrease in the mediastinal mass and supraclavicular adenopathies.
In the PET result sent in June 2018, it is described that there are no hypermetabolic foci in the cervical region
lower cervical region or mediastinum, which corresponds with a positive response to the treatments applied. At that time, the patient was discharged by his oncologist in his home country and follow-up every 3 months was indicated.
In the case of Escozul™, he will remain on treatment until 6 months after the first cancer-free test is completed. At that time we will also be able to discharge you from our protocol.
In this case, the combined use of Escozul™ with chemotherapy and radiotherapy made it possible for the patient to overcome the disease within one year and have a better outlook for future evolution.
As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.
It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.
If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.
To enter the protocol you must send us an email to: email@example.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.
Prepared by LifEscozul™ Group July/2018